Article

The Psychosocial Impact of Cancer: A CPAN Advocacy Chat

On August 10 at 12 p.m. ET, the CPAN Advocacy Chat series will explore the psychosocial impact of a cancer diagnosis on a patient, their family, and friends. Lauren Chatalian, MSW, LCSW, of CancerCare will be sharing ways to promote effective communication between parents/guardians and children of families impacted by cancer in a developmentally appropriate manner. The chat will focus on navigating practical concerns families may experience throughout the cancer continuum, such as loss of income, new health restrictions, and more.

A cancer diagnosis is more than a physical diagnosis. Each patient experiences various psychosocial effects due to the diagnosis, and so do the loved ones of the patient. Depression, anger, anxiety, and other psychological symptoms can cause interruptions in care, careers, and relationships. Treating these symptoms are crucial to ensuring treatment is successful. In addition to discussing the practical concerns of families navigating the cancer continuum, COA Director of Patient Advocacy and Education Rose Gerber and Lauren will discuss the resources that CancerCare has available for those in need. As the Director of Advocacy and an Oncology Social Worker for CancerCare, Chatalian works to provide patients with the resources they need and advocate for expanded resource pools so no patients or their families fall through the cracks.

Click here to register.

Related Videos
Image of Dr. Salani.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Fakih.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
1 expert is featured in this series.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.